Business
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis
KAWASAKI, Japan, December 17, 2025--PeptiDream is advancing the oral IL-17a/ IL-17F dual inhibitor peptide program into IND-enabling studies, while exploring strategic partnerships.
About this update from Peptidream Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/c038a4732d57d1aa7a5ffddc86b5e68e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lSOfrYfT.PSsIDv1VZ8foQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c038a4732d57d1aa7a5ffddc86b5e68e","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/7Mf6ltngVOLDpHEJZvlF6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/c038a4732d57d1aa7a5ffddc86b5e68e","width":1024,"height":512}},"lazy":false},{"type":"text","content":"KAWASAKI, Japan, December 17, 2025--(BUSINESS WIRE)--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587) announced its second oral peptide therapeutic program entering into its Clinical Development Portfolio – a dual IL-17A and IL-17F macrocyclic peptide inhibitor targeting the major dimeric forms of interleukin-17 (IL-17AA, IL-17AF, IL-17FF) – at their 2025 R&D Day held on December 5, 2025. The development candidate demonstrated biologic-like efficacy in preclinical models when orally administered, aiming to deliver a deeper and more durable response across skin and musculoskeletal manifestations, improving patient quality of life.","length":744,"tagName":"p"},{"type":"text","content":"The IL17 pathway is a clinically validated therapeutic target across several major autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. Although today’s approved IL17 inhibitors deliver excellent clinical outcomes, all are injectable biologics, which can limit convenience and long-term accessibility. PeptiDream’s oral IL17 macrocyclic peptide is designed to change this paradigm—offering the potential for biologiclike efficacy with the benefits of oral administration, as well as the versatility for monotherapy or combination therapy with TNF or JAK inhibitors, providing new options for patients with difficulttotreat disease.","length":669,"tagName":"p"},{"type":"text","content":"Key Highlights of the Program:","length":30,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"t...